Immunovant, Inc. [IMVT]

Source: 

Company Overview

Immunovant, Inc is a clinical-stage immunology company pursuing a broad anti-FcRn strategy based on the potential best-in-class profile of our lead asset, IMVT-1402, and informed by the breadth of the class, in which 23 indications have been publicly announced for study by multiple companies to date.